Placebo ocrelizumab
Sponsors
F. Hoffmann-La Roche AG
Conditions
Primary Progressive Multiple Sclerosis (PPMS)Relapsing Multiple Sclerosis (MS)
Phase 3
A Phase IIIb Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis
Active, not recruitingCTIS2023-506467-34-00
Start: 2020-10-20Target: 357Updated: 2025-11-17
A Phase IIIB Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults with Primary Progressive Multiple Sclerosis
Active, not recruitingCTIS2023-506515-18-00
Start: 2020-10-23Target: 310Updated: 2025-03-26